Back
 OJPed  Vol.3 No.3 , September 2013
Comparative efficacy of levofloxacin and ceftriaxone in the treatment of community acquired pneumonia in children
Abstract: Pneumonia is a common cause of mortality and morbidity in under-5 children throughout the world. Globally an estimated 156 million new episodes of pneumonia occur each year in children and 2 million children die from pneumonia each year which is 20 percent of all deaths of children under five years old. Ceftriaxone is a commonly used drug for empiric treatment of community acquired pneumonia (CAP) in children. Levofloxacin may be an adequate option for empiric therapy in treatment of CAP in children because it gives the broad spectrum activity against both bacterial and atypical pathogens causing CAP and studies suggest that it can be safely used in children. This open labeled, randomized, comparative clinical trial was carried out in the Department of Pediatrics, Sylhet MAG Osmani Medical College Hospital, Bangladesh during January, 2011 & December, 2012 to compare the efficacy of levofloxacin and ceftriaxone in the treatment CAP in children. A total 70 cases of CAP were enrolled. 35 cases were allocated to levofloxacin group and another 35 cases to ceftriaxone group. At first the study cases were selected by systematic random sampling. Group allocation to either levofloxacin or ceftriaxone group was done by lottery method. Total duration for receiving study drugs was seven days. Dose of levofloxacin was 10 mg/kg/day children ≥5 years, where as it was 10 mg/kg 12 hourly in 6 months to <5 years age groups. Dose of ceftriaxone was 75 mg/kg/day. Response to treatment was assessed initially after 3 days and also after 7 days by clinical symptoms and signs. Clinical cure rate was determined by disappearance of the clinical signs and symptoms of pneumonia and resolution of radiological findings reported at admission. Clinical responses were categorized as cured and treatment failure. 91.43% cases were cured in levofloxacin group, whereas cure rate of ceftriaxone group was 68.57% which was statistically significant (p = 0.0168). Adverse effects of levofloxacin were found as skin rash in 1 case and vomiting in 2 cases whereas skin rash was found in 1 case in ceftriaxone group. So it can be concluded that levofloxacin is more effective than ceftriaxone in the treatment of CAP in children.
Cite this paper: Hoque, M. , Nuruzzaman, M. and Malik, M. (2013) Comparative efficacy of levofloxacin and ceftriaxone in the treatment of community acquired pneumonia in children. Open Journal of Pediatrics, 3, 266-269. doi: 10.4236/ojped.2013.33046.
References

[1]   Sectish, C.T. and Prober, C.G. (2007) Pneumonia. In: Kliegman, R.M., Behrman, R.E., Jenson, H.B. and Stanton, B.F., Eds., Nelson Text Book of Paediatrics, Saunders, New Delhi, 1795-1798.

[2]   Kabra, S.K., Lodha, R. and Pandy, R.M. (2010) Antibiotic for community acquired pneumonia in children. Cochrane Database of Systematic Reviews, 17. doi:10.1002/14651858.CD004874.pub3

[3]   UNICEF/WHO (2013) Pneumonia: The forgotten killer of children. http://www. who. int/ maternal_child_adolesc ent/documents/9 280640489/en/

[4]   Naheed, A., Saha, S.K., Breiman, R.F., Khatun, F., Brooks, W.A., Arifeen, S.E., et al. (2009) Multihospital surveillance of pneumonia burden among children aged <5 years hospitalized for pneumonia in Bangladesh. CID, 48, S82-S89. doi:10.1086/596485

[5]   Bradley, J.S., Arguedas, A., Blumer, J.L., Saéz-Llorens, X., Melkote, R. and Noel, G.J. (2007) Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia. The Pediatric Infectious Disease Journal, 26, 868-878. doi:10.1097/INF.0b013e3180cbd2c7

[6]   Chein, S., Wells, T.G., Blumer, J.L., Kearnset, G.L., Bradly, J.S., Bocchini, J.A., et al. (2005) Levofloxacin pharmacokinetic in children. The Journal of Clinical Pharmacology,45,153-160.doi:10. 1177/009 1270004271944

[7]   Rang, H.P., Dale, M.M., Ritter, J.M. and Flower, R.J. (2008) Rang and dale’s pharmacology. Churchill Livingstone Elsevier, New York, 660-678.

[8]   Pallares, R., Linares, J., Vadillo, M., Cabellos, C., Manresa, F., Viladrich, P.F., Martin, R. and Gudiol, F. (1995) Penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona. The New England Journal of Medicine, 333, 474-480. doi:10.1056/NEJM199508243330802

[9]   WHO (2011) Fluroquinolones use in paediatrics: Focus on safety and place in therapy. 18th Expart Committee on the Selection and Use of Essential Medicines, Gneva, 1-13.

[10]   Bradly, J.A. (2013) Multicentre, randomized, open-label, comparative study to compare the efficacy and safety of levofloxacin and standard of care therapy in the treatment of children with community-acquired pneumonia in the hospitalized or outpatient setting. http://filehosting.pharmacon.com

[11]   Chambers, H.F. and Deck, D.H. (2009) Sulfonamides, trimethoprim & quinolones. In: Katzung, B.G., Master, S.B. and Trevor, J.A., Eds., Basic and Clinical Pharmacology, Prentice-Hall International Inc., New Delhi, 815-822.

[12]   File, J.R., Segreti, J., Dunbar, L., Player, R., Kohler, R., Williams, R.R., et al. (1997) A multicentre, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents and Chemother, 41, 1965-1972.

[13]   Prescot, L.M. (2002) Highlights of the 41st interscience conference on antimicrobial agents and chemotherapy. Pharmacy & Therapeutics, 77, 143-146.

 
 
Top